Novo Nordisk Sues Connecticut Firm Over Illegal Semaglutide Claims

Novo Nordisk has initiated legal action against a Connecticut company allegedly selling compounded products that claim to contain semaglutide, the active compound in Ozempic, a medication manufactured by Novo Nordisk. The lawsuit asserts that these products misleadingly suggest approval by the U.S. Food and Drug Administration (FDA), thus infringing both state and federal laws. For professionals keen on the developments of this case, further details can be accessed through Law360’s report.